NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed an expansion of its partnership with Maastricht University to develop genetic and epigenetic cancer diagnostics.

Under the terms of the multiyear deal, MDxHealth will collaborate with Maastricht's Faculty of Health, Medicine, and Life Sciences institute and its School for Oncology and Developmental Biology to develop genetic and epigenetic assays for diagnosing, staging, and treating cancer patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.